Get the Stockscreener App
3.00
0.66%
-0.02
Adc Therapeutics Sa stock is traded at $3.00, with a volume of 148.16K.
It is down -0.66% in the last 24 hours and down -8.81% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
See More
Previous Close:
$3.02
Open:
$2.97
24h Volume:
148.16K
Relative Volume:
0.43
Market Cap:
$293.93M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-1.3216
EPS:
-2.27
Net Cash Flow:
$-121.90M
1W Performance:
-0.33%
1M Performance:
-8.81%
6M Performance:
-38.78%
1Y Performance:
+275.00%
1-Day Range:
$2.95
$3.07
1-Week Range:
$2.81
$3.11
52-Week Range:
$0.3599
$6.04
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting - StockTitan
ADC Therapeutics to Present at November 2024 Investor Conferences - BioSpace
ADC Therapeutics to Present at November Investor Conferences - StockTitan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - Nasdaq
ADC Therapeutics (ADCT) Set to Announce Earnings on Thursday - MarketBeat
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - GlobeNewswire Inc.
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - BioSpace
Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT) - Yahoo Finance
Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030 | DelveInsight - The Malaysian Reserve
Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029 - PR Newswire UK
The Manufacturers Life Insurance Company Purchases Shares of 26,938 ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Sees Large Growth in Short Interest - MarketBeat
Adc Therapeutics SA’s Shares Reel: -23.19% Quarterly Revenue Decline Amid 297.81M Market Cap - The InvestChronicle
Adc Therapeutics SA (ADCT) rating initates by Cantor Fitzgerald - Knox Daily
ADC Therapeutics SA's (NYSE:ADCT) institutional investors lost 10% over the past week but have profited from longer-term gains - Simply Wall St
Antibody Drug Conjugates Industry Report (2024-2032) - GlobeNewswire
Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 PlayersADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More - 24matins.uk
ADC Therapeutics : Subgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65 (Form 6-K) - Marketscreener.com
Antibody Drug Conjugates Market Advancements Highlighted by Research 2024-2033 – Outlook, Overview - WhaTech
ADC Therapeutics SA (NYSE:ADCT) Shares Bought by XTX Topco Ltd - Defense World
Rhumbline Advisers Purchases Shares of 85,977 ADC Therapeutics SA (NYSE:ADCT) - Defense World
Adc Therapeutics (ADCT) Price Target Increased by 9.79% to 8.77 - MSN
Wall Street SWOT: ADC Therapeutics stock faces challenges amid potential growth - Investing.com India
474,744 Shares in ADC Therapeutics SA (NYSE:ADCT) Purchased by Affinity Asset Advisors LLC - MarketBeat
Affinity Asset Advisors LLC Makes New Investment in ADC Therapeutics SA (NYSE:ADCT) - Defense World
205,221 Shares in ADC Therapeutics SA (NYSE:ADCT) Purchased by Bank of New York Mellon Corp - MarketBeat
205,221 Shares in ADC Therapeutics SA (NYSE:ADCT) Bought by Bank of New York Mellon Corp - Defense World
Adc Therapeutics SA [ADCT] Investment Guide: What You Need to Know - Knox Daily
Acadian Asset Management LLC Invests $51,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Buying Buzz: Agree Realty Corp. [ADC] Director RAKOLTA JOHN JR purchases 20,000 shares of the company - Knox Daily
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue - BioSpace
ADC Therapeutics SA (NYSE:ADCT) Short Interest Down 8.8% in August - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Declines By 8.8% - Defense World
Addus HomeCare (NASDAQ:ADUS) Reaches New 12-Month High at $136.12 - MarketBeat
ADC Therapeutics : Cantor Global Healthcare Conference Presentation - Marketscreener.com
Daily Progress: Agree Realty Corp. (ADC) Drop -0.96, Closing at 75.97 - The Dwinnex
ADC Therapeutics : Cantor Global Healthcare Conference 2024 Presentation - Marketscreener.com
Agree Realty (NYSE:ADC) Reaches New 52-Week High at $77.19 - MarketBeat
Quest Partners LLC Sells 20,070 Shares of Agree Realty Co. (NYSE:ADC) - MarketBeat
ADC Therapeutics (NYSE:ADCT) Trading 0.5% Higher - MarketBeat
Adc Therapeutics SA (ADCT) is a good investment, but the stock may be overvalued - US Post News
Insider’s View: Deciphering Adc Therapeutics SA (ADCT)’s Financial Health Through Ratios - The Dwinnex
ADCT (Adc Therapeutics SA) may reap gains as insiders became active recently - Knox Daily
ADC Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance UK
Adc Therapeutics SA (ADCT)’s stock performance: a year in review - US Post News
Are Smart Investors Making the Right Decision? Adc Therapeutics SA (ADCT) - SETE News
A Closer Look at Adc Therapeutics SA (ADCT) Stock Gains - The InvestChronicle
Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC - Seeking Alpha
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):